奥沙利铂或紫杉醇联合5-氟尿嘧啶方案在胃癌术后化疗中的疗效和安全性研究

目的探讨奥沙利铂或紫杉醇联合5-氟尿嘧啶(5-Fu)治疗胃癌术后患者的临床疗效与安全性。方法对2010年6月至2012年6月间收治的76例行胃癌根治术患者按其入院顺序进行分组,奥沙利铂组(38例)行奥沙利铂联合5-Fu方案化疗,紫杉醇组(38例)行紫杉醇联合5-Fu方案化疗。随访17个月,分析两组患者的临床疗效。结果 76例患者随访率为100%。两组治疗总有效率比较,差异无统计学意义(P>0.05)。奥沙利铂组中位无进展生存时间为6.2个月,中位生存时间则为9.8个月,1年生存率为65.8%(25/38);紫杉醇组中位无进展生存时间为6.7个月,中位生存时间则为10.7个月,1年生存率为71.1%(27/38),两组比较,差异无统计学意义(P>0.05)。两组患者出现的不良反应均可以耐受,且均无严重不良反应发生。结论奥沙利铂或紫杉醇联合5-Fu方案对胃癌术后患者进行治疗,具有较理想的临床疗效,不良反应均可耐受,用药安全性较高,极具临床应用价值。

Efficacy and safety study of oxaliplatin combined with fluorouracil or paclitaxel combined with fluorouracil regimen in postoperative chemotherapy of gastric cancer

Objective To compare the two chemotherapy schemes-oxaliplatin or paclitaxel combined with fluorouracil（5-Fu） in treatment of of postoperative gastric cancer patients and discuss the clinical efficacy and safety.Methods From June 2010 to June 2012,76 cases of gastric cancer were enrolled in the study and divided randomly into two groups：oxaliplatin group（38 cases）,accepting oxaliplatin combined with 5-Fu regimen;paclitaxel group（38 cases）,accepting paclitaxel combined with 5-Fu regimen.After the follow-up of 17 months,the clinical effects of the two groups were compared.Results All the patients completed followed-up and the followed-up rate was 100%.The total efficiency of two groups have no difference（P 〉 0.05）.The median progression-free survival（PFS） of oxaliplatin group was 6.2 months,median survival time 9.8 months,1 year survival rate 65.8%（25 /38）;The PFS of paclitaxel group was6.7 months,median survival time was 10.7 months,1 year survival rate 71.1%（27 /38）,and there were no significant differece between the two groups（P 〉 0.05）.The adverse reactions of two groups were both tolerable and there were no serious adverse reactions.Conclusion For postoperative gastric cancer patients undergoing chemotherapy,oxaliplatin or paclitaxel combined with 5-FU can achieve good clinical effect,and the adverse reactions can be tolerable.For their good curative effects and safety,they have great value in clinical application.